ClinicalTrials.gg
CompletedNCT05442190Updated Nov 17, 2026Results posted

Topical SGX302 for Mild-to-Moderate Psoriasis

A Phase 2 interventional study of Hypericin in Psoriasis, Plaque Psoriasis and Psoriasis Vulgaris, sponsored by Soligenix. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Soligenix · Phase 2, Interventional, and Treatment

How we know

Updated Nov 17, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 766 studies in Psoriasis with a site in United States — 57 open to participants now, 88 under way, 19 of them phase 3. Psoriasis · United States.

Enrollment
587th of 675
15 · median 77
Started
2022
with 36 others
Phase 2
200 of 766
5 open now
Registered
657th of 766
by date

Among the 766 studies in Psoriasis with a site in United States, this one is the 587th largest by enrollment of the 675 interventional ones that give a count, is one of 37 that started in 2022, is one of 200 in phase 2, and was the 657th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

57 of the 766 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

52 more — sign in →

All 57 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 766 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

To evaluate SGX302 (topical hypericin ointment and gel) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.

03

Conditions studied

  • Psoriasis
  • Plaque Psoriasis
  • Psoriasis Vulgaris

Browse trials for

Keywords

  • Hypericin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6-months duration that involves the body (trunk and/or limbs) that is amenable to topical treatment and opaque coverage after application.
  • Have a static Investigator Global Assessment (IGA)/Psoriasis Area and Severity Index (PASI) of disease severity of mild or moderate on the body (trunk and/or limbs).
  • Have lesions involving 2-30% of the body (trunk and/or limbs). For subjects with scalp psoriasis included in the treatment area, the total treatment area on body and scalp must not exceed 30%.

Exclusion criteria

Exclusion Criteria:

  • Use of topical anti psoriatic therapy within one week prior to the beginning of the study and willing to not use other psoriasis treatments for 4 weeks following completion of the treatment portion of the study.
  • Received systemic biologic therapy to treat psoriasis within 12 weeks prior to the beginning of the study.
  • Received systemic psoriasis therapy within 4 weeks prior to the beginning of the study.
  • Received phototherapy (including laser) or photodynamic (light activated drug) therapy within 4 weeks prior to the beginning of the study.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Cohort 1 - SGX302 Ointment (0.25 % Hypericin)

    SGX302 (0.25 % hypericin) ointment will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm\^2 with a gradual escalation of light therapy up to 25 J/cm\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks.

    Drug: Hypericin

  • Experimental
    Cohort 2 - SGX302 Ointment (0.25 % Hypericin)

    SGX302 (0.25 % hypericin) ointment will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm\^2 with a faster escalation of light therapy up to 25 J/cm\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks.

    Drug: Hypericin

  • Experimental
    Cohort 3 - SGX302 Gel (0.25 % Hypericin)

    SGX302 (0.25 % hypericin) gel will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm\^2 with a faster escalation of light therapy up to 40 J/cm\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks.

    Drug: Hypericin

Interventions

  • SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.

    Also known as: SGX302

06

What researchers measure

Primary outcomes

  1. Number of Patients That Achieve a 0 or 1 Score Using the 5-point Investigator's Global Assessment Scale

    The percentage of patients in each treatment group that achieve a 0 or 1 score (Clear or Almost Clear) evaluation using the 5-point Investigator's Global Assessment (IGA) scale. The 5-point IGA scale: * Score 0: Clear - No signs of psoriasis; post-inflammatory hyperpigmentation may be present * Score 1: Almost Clear - No thickening; normal to pink coloration; no to minimal focal scaling * Score 2: Mild - Just detectable to mild thickening; pink to light red coloration; predominantly fine scaling * Score 3: Moderate - Clear distinguishable to moderate thickening; dull to bright red; moderate scaling * Score 4: Severe - Severe thickening with hard edges; bright to deep red coloration; severe/coarse scaling covering almost all lesions

    Time frame: 18 weeks

Secondary outcomes

  1. SkinDex-29 Score

    The SkinDex-29 is a validated quality of life questionnaire that measures the effects of skin diseases on a person's life. It is a series of 30 questions assessing the participant's opinion of the impact of their disease on their life in the previous 4 weeks. Answers are scored from 1 (never), 2 (rarely), 3 (sometimes), 4 (often) to 5 (all the time) and are summed to get a total score. The minimum score possible is 30 and the maximum score possible is 150. A lower score means a better outcome.

    Time frame: Baseline, End of Treatment (Week 18)

  2. Dermatology Life Quality Index Score

    The Dermatology Life Quality Index was developed as a general quality of life instrument to measure the impact of chronic skin disease on patients. The aim of the questionnaire is to measure how much the participant's skin problems affected their life over the past week. The questionnaire contains 10 questions with responses ranging from 0 (not at all), 1 (a little), 2 (a lot) to 3 (very much) that are summed to get a total score. The minimum score possible is 0 and the maximum score possible is 30. A lower score means a better outcome.

    Time frame: Baseline, End of Treatment (Week 18)

07

Results

Posted Nov 17, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort 1 - SGX302 Ointment (0.25 % Hypericin)Cohort 2 - SGX302 Ointment (0.25 % Hypericin)Cohort 3 - SGX302 Gel (0.25 % Hypericin)
Started555
Completed543
Not completed012
Withdrew: Withdrawal by subject012

Outcome measures

PrimaryNumber of Patients That Achieve a 0 or 1 Score Using the 5-point Investigator's Global Assessment Scale

The percentage of patients in each treatment group that achieve a 0 or 1 score (Clear or Almost Clear) evaluation using the 5-point Investigator's Global Assessment (IGA) scale. The 5-point IGA scale: * Score 0: Clear - No signs of psoriasis; post-inflammatory hyperpigmentation may be present * Score 1: Almost Clear - No thickening; normal to pink coloration; no to minimal focal scaling * Score 2: Mild - Just detectable to mild thickening; pink to light red coloration; predominantly fine scaling * Score 3: Moderate - Clear distinguishable to moderate thickening; dull to bright red; moderate scaling * Score 4: Severe - Severe thickening with hard edges; bright to deep red coloration; severe/coarse scaling covering almost all lesions

Time frame:
18 weeks
Reported as:
Count of participants · Participants
Number of Patients That Achieve a 0 or 1 Score Using the 5-point Investigator's Global Assessment Scale
ParticipantsCohort 1 - SGX302 Ointment (0.25 % Hypericin)Cohort 2 - SGX302 Ointment (0.25 % Hypericin)Cohort 3 - SGX302 Gel (0.25 % Hypericin)
Number of Patients That Achieve a 0 or 1 Score Using the 5-point Investigator's Global Assessment Scale011
SecondarySkinDex-29 Score

The SkinDex-29 is a validated quality of life questionnaire that measures the effects of skin diseases on a person's life. It is a series of 30 questions assessing the participant's opinion of the impact of their disease on their life in the previous 4 weeks. Answers are scored from 1 (never), 2 (rarely), 3 (sometimes), 4 (often) to 5 (all the time) and are summed to get a total score. The minimum score possible is 30 and the maximum score possible is 150. A lower score means a better outcome.

Time frame:
Baseline, End of Treatment (Week 18)
Reported as:
Mean · Scores on a Scale
SkinDex-29 Score
Scores on a ScaleCohort 1 - SGX302 Ointment (0.25 % Hypericin)Cohort 2 - SGX302 Ointment (0.25 % Hypericin)Cohort 3 - SGX302 Gel (0.25 % Hypericin)
Baseline76 ± 3059 ± 1592 ± 26
End of Treatment74 ± 2055 ± 2478 ± 23
SecondaryDermatology Life Quality Index Score

The Dermatology Life Quality Index was developed as a general quality of life instrument to measure the impact of chronic skin disease on patients. The aim of the questionnaire is to measure how much the participant's skin problems affected their life over the past week. The questionnaire contains 10 questions with responses ranging from 0 (not at all), 1 (a little), 2 (a lot) to 3 (very much) that are summed to get a total score. The minimum score possible is 0 and the maximum score possible is 30. A lower score means a better outcome.

Time frame:
Baseline, End of Treatment (Week 18)
Reported as:
Mean · Scores on a Scale
Dermatology Life Quality Index Score
Scores on a ScaleCohort 1 - SGX302 Ointment (0.25 % Hypericin)Cohort 2 - SGX302 Ointment (0.25 % Hypericin)Cohort 3 - SGX302 Gel (0.25 % Hypericin)
Baseline6 ± 53 ± 116 ± 10
End of Treatment5 ± 34 ± 412 ± 6

Adverse events

Collected over Adverse events were collected from enrollment until end of follow-up, up to 22 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 - SGX302 Ointment (0.25 % Hypericin)0/5 (0%)0/5 (0%)4/5 (80%)
Cohort 2 - SGX302 Ointment (0.25 % Hypericin)0/5 (0%)0/5 (0%)3/5 (60%)
Cohort 3 - SGX302 Gel (0.25 % Hypericin)0/5 (0%)0/5 (0%)3/5 (60%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventCohort 1 - SGX302 Ointment (0.25 % Hypericin)Cohort 2 - SGX302 Ointment (0.25 % Hypericin)Cohort 3 - SGX302 Gel (0.25 % Hypericin)
Left axillary lymphadenopathyBlood and lymphatic system disorders1/50/50/5
Eye irritationEye disorders0/51/50/5
Pain localizedGeneral disorders0/51/50/5
Upper respiratory tract infectionInfections and infestations1/51/50/5
NasopharyngitisInfections and infestations1/50/50/5
InfluenzaInfections and infestations0/51/50/5
Left lower leg abscessInfections and infestations0/50/51/5
SunburnInjury, poisoning and procedural complications1/50/50/5
Muscle strainInjury, poisoning and procedural complications1/50/50/5
Contusion of toeInjury, poisoning and procedural complications1/50/50/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1 - SGX302 Ointment (0.25 % Hypericin)Cohort 2 - SGX302 Ointment (0.25 % Hypericin)Cohort 3 - SGX302 Gel (0.25 % Hypericin)Total
Mean54 ± 5.045 ± 10.856 ± 9.552 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 - SGX302 Ointment (0.25 % Hypericin)Cohort 2 - SGX302 Ointment (0.25 % Hypericin)Cohort 3 - SGX302 Gel (0.25 % Hypericin)Total
Female44210
Male1135
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 - SGX302 Ointment (0.25 % Hypericin)Cohort 2 - SGX302 Ointment (0.25 % Hypericin)Cohort 3 - SGX302 Gel (0.25 % Hypericin)Total
American Indian or Alaska Native0000
Asian0101
Native Hawaiian or Other Pacific Islander0101
Black or African American0000
White53513
More than one race0000
Unknown or Not Reported0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 - SGX302 Ointment (0.25 % Hypericin)Cohort 2 - SGX302 Ointment (0.25 % Hypericin)Cohort 3 - SGX302 Gel (0.25 % Hypericin)Total
Hispanic or Latino3238
Not Hispanic or Latino2327
Unknown or Not Reported0000
08

Study locations

1 site
  • Therapeutics Clinical Research
    San Diego, California 92123, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Oct 2025, 34 months.

Results were first posted in Nov 2026, 1 year after primary completion.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 34 months is above that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2022
First posted
Jul 1, 2022
StartActual
Dec 14, 2022
Primary completionActual
Oct 22, 2025
CompletionActual
Nov 17, 2025
Results first posted
Nov 17, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 17, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of patients that achievePatients That Achieve a 0 or 1 score usingScore Using the 5-point Investigator's Global Assessment scaleScaleTime frame: 18 weeks
Nov 17, 2026
Documents
Secondary outcomes
2 added, 3 removed
What changed in the outcomes
  • AddedSkinDex-29 ScoreTime frame: Baseline, End of Treatment (Week 18)
  • AddedDermatology Life Quality Index ScoreTime frame: Baseline, End of Treatment (Week 18)
  • RemovedNumber of patients achieving a ≥75% improvement in Psoriasis Area and Severity IndexTime frame: 18 weeks
  • RemovedNumber of patients achieving a ≥90% improvement in Psoriasis Area and Severity IndexTime frame: 18 weeks
  • RemovedNumber of patients achieving a 100% improvement in Psoriasis Area and Severity IndexTime frame: 18 weeks
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of patients that achievePatients That Achieve a 0 or 1 score usingScore Using the 5-point Investigator's Global Assessment scaleScaleTime frame: 18 weeks
    Secondary outcomes 2 added, 3 removed
    What changed in the outcomes
    • AddedSkinDex-29 ScoreTime frame: Baseline, End of Treatment (Week 18)
    • AddedDermatology Life Quality Index ScoreTime frame: Baseline, End of Treatment (Week 18)
    • RemovedNumber of patients achieving a ≥75% improvement in Psoriasis Area and Severity IndexTime frame: 18 weeks
    • RemovedNumber of patients achieving a ≥90% improvement in Psoriasis Area and Severity IndexTime frame: 18 weeks
    • RemovedNumber of patients achieving a 100% improvement in Psoriasis Area and Severity IndexTime frame: 18 weeks
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05442190
Lead sponsor
Soligenix
Responsible party
Sponsor
First posted
Jul 1, 2022
Start date
Dec 14, 2022
Primary completion
Oct 22, 2025
Completion
Nov 17, 2025
Results posted
Nov 17, 2026
Last update
Nov 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hypericin

Start the discussion